Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Theramed (Delatestryl And Viroptic Drug Rights)

M&A STATUS
Asset Purch. LATEST DEAL TYPE
1 FINANCING ROUNDS
Description

Portfolio of drug rights in Ontario, Canada. The portfolio comprises of two drugs, Delatstryl, a sterile, oily testosterone enanthate remedy used to treat primary and secondary testosterone deficiency in men and Viroptic, a prescription antiviral eye drop used to treat the epithelial keratitis herpes infection of the eye.

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Primary Industry
Other Commercial Services
Other Industries
Buildings and Property
Pharmaceuticals
Primary Office
  • 6891 Edwards Boulevard
  • Mississauga, Ontario L5T 2T9
  • Canada

Theramed (Delatestryl And Viroptic Drug Rights) Valuation and Funding

Deal Type Date Amount Post-Val Valuation/
EBITDA
Debt Status

This information is reserved for PitchBook Platform users. To explore Theramed (Delatestryl And Viroptic Drug Rights)‘s full profile, request access.

Request full access to PitchBook

Theramed (Delatestryl And Viroptic Drug Rights) Former Investors

Investor Name Investor Type Holding Participating Rounds Investor Since Board Seat Contact Info

This information is reserved for PitchBook Platform users. To explore Theramed (Delatestryl And Viroptic Drug Rights)‘s full profile, request access.

Request full access to PitchBook